173 related articles for article (PubMed ID: 18815556)
1. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
3. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
4. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
6. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells.
Sponaas A; Carstens C; Koch N
Gene Ther; 1999 Nov; 6(11):1826-34. PubMed ID: 10602378
[TBL] [Abstract][Full Text] [Related]
7. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
8. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response.
Toda M; Kasai M; Hosokawa H; Nakano N; Taniguchi Y; Inouye S; Kaminogawa S; Takemori T; Sakaguchi M
Eur J Immunol; 2002 Jun; 32(6):1631-9. PubMed ID: 12115646
[TBL] [Abstract][Full Text] [Related]
10. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
11. A novel domain on HLA-DRbeta chain regulates the chaperone role of the invariant chain.
Neumann J; Koch N
J Cell Sci; 2006 Oct; 119(Pt 20):4207-14. PubMed ID: 16984974
[TBL] [Abstract][Full Text] [Related]
12. Target HCV NS3 CD4+ Th1 epitope to major histocompatibility complex class II pathway.
Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
Biotechnol Lett; 2006 Jan; 28(1):3-8. PubMed ID: 16369867
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
14. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
Rodeberg DA; Erskine C; Celis E
J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
18. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.
Bischof F; Wienhold W; Wirblich C; Malcherek G; Zevering O; Kruisbeek AM; Melms A
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12168-73. PubMed ID: 11593032
[TBL] [Abstract][Full Text] [Related]
19. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]